ARCALIS to Present a Poster at the 11th Annual Meeting of the Japanese Society for Genome Editing
Dr. Yanagiya of the Business Development Department at ARCALIS. Inc. will present a poster at the 11th Annual Meeting of the Japanese Society for Genome Editing, to be held at Kyoto University Clock Tower Centennial Hall from June 15–17, 2026. We warmly invite conference attendees to visit our poster presentation.
【Event details】
Official website: https://jsgedit.jp/meeting/11/index.html
Date: June 15th (Mon) -17th (Wed), 2026
Venue: Clock Tower Centennial Hall, Kyoto University
Access: https://www.kyoto-u.ac.jp/ja/about/facilities/campus/clocktower
【Poster presentation】
Title: ARCALIS: A CDMO advancing mRNA therapeutics for genome editing from mRNA design to manufacturing
Presenter: Dr. Akiko Yanagiya
Poster No.: P-54
Date: June 17th (Wed), 2026. 11:15 ~ 12:45
【Abstract】
ARCALIS provides integrated services from mRNA design to large‑scale GMP manufacturing as a CDMO specializing in mRNA therapeutics, including vaccines for infectious diseases and cancer, and genome editing-based treatments of rare diseases. mRNA therapeutics have emerged as a versatile platform enabling potent expression of therapeutic proteins, gene‑editing Cas nucleases and adenine base editors. Several mRNA‑based genome editing therapeutics have already progressed into clinical trials. Compared with viral vector-based technologies such as adeno‑associated virus (AAV), mRNA therapeutics offer distinct advantages: mRNA does not integrate into the host genome, thereby reducing the risk of insertional mutagenesis, and enables controllable, transient protein expression. In addition, mRNA manufacturing allows flexible and rapid design, avoids vector immunity and insert size constraints associated with AAV, and supports repeat dosing. In this presentation, we introduce three proprietary technologies that enhance high quality and scalable mRNA manufacturing to accelerate the development of mRNA‑based genome editing:
(1) an organ‑selective mRNA delivery platform enabled by optimized lipid compositions.
(2) an innovative machine learning-based codon optimization method, HARNATM, developed in collaboration with Hitachi, Inc. using mRNA stability
prediction model.
(3) an original self‑amplifying RNA (saRNA) platform enabling efficient and sustained protein expression.
Collectively, these technologies support the production of safer, more effective mRNA therapeutics and advance clinical application of genome editing.